Since about half of NSCLC cells harbor p53 gene mutations, which are associated with poor prognosis [96, 97], the effect of BTZ versus HMSN-BTZ was investigated for wild-type p53 cells compared to mutant p53 cells [95]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.